Expanding the clinical and geographical spectrum of PARK-LRRK2 p.(Asn1437His): first report in a Swiss family

INTRODUCTION: Pathogenic variants in the LRRK2 gene represent the most common monogenic cause of Parkinson’s disease. Individual variants differ in frequency, geographical distribution and genotype-phenotype associations. Here, we report a Swiss family with multiple affected individuals carrying a very rare ROC-domain variant and provide a comprehensive characterisation of their clinical phenotype. CLINICAL FINDINGS: Age at onset was earlier than typically reported for PARK-LRRK2. Leg tremor was frequently the initial presenting symptom, followed by the development of an asymmetric akinetic-rigid syndrome with a clear dopaminergic response. Constipation was commonly reported, whereas significant cognitive symptoms were not evident. Notably, despite the high penetrance of the variant, disease progression was relatively mild. PRIMARY DIAGNOSIS: Genetic testing identified a heterozygous missense variant in the LRRK2 gene (c.4309A>C, p.(Asn1437His)), classified as likely pathogenic according to ACMG criteria. CONCLUSION: The present work expands both the geographical distribution of this rare ROC-domain variant and suggests that it may be associated with earlier onset but not necessarily greater disease severity. Continued characterisation of rare LRRK2 variants is essential for refining genotype-phenotype correlations and supporting emerging targeted therapies.

Authors

Institutions

Publication Details

Journal
Swiss Medical Weekly
Published
2026-11-16
DOI
https://doi.org/10.57187/5519
Primary Topic
Parkinson's Disease Mechanisms and Treatments
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Expanding the clinical and geographical spectrum of PARK-LRRK2 p.(Asn1437His): first report in a Swiss family

Deborah Bartholdi, Gerd Tinkhauser, Paul Krack, Georg Kägi et al.
2 links
Swiss Medical Weekly
Parkinson's Disease Mechanisms and Treatments
article

Expanding the clinical and geographical spectrum of PARK-LRRK2 p.(Asn1437His): first report in a Swiss family

Deborah Bartholdi, Gerd Tinkhauser, Paul Krack, Georg Kägi, Anina Bauer, Jacob Clausen, Christiane Zweier, Mario Sousa
article en

Abstract

INTRODUCTION: Pathogenic variants in the LRRK2 gene represent the most common monogenic cause of Parkinson’s disease. Individual variants differ in frequency, geographical distribution and genotype-phenotype associations. Here, we report a Swiss family with multiple affected individuals carrying a very rare ROC-domain variant and provide a comprehensive characterisation of their clinical phenotype. CLINICAL FINDINGS: Age at onset was earlier than typically reported for PARK-LRRK2. Leg tremor was frequently the initial presenting symptom, followed by the development of an asymmetric akinetic-rigid syndrome with a clear dopaminergic response. Constipation was commonly reported, whereas significant cognitive symptoms were not evident. Notably, despite the high penetrance of the variant, disease progression was relatively mild. PRIMARY DIAGNOSIS: Genetic testing identified a heterozygous missense variant in the LRRK2 gene (c.4309A>C, p.(Asn1437His)), classified as likely pathogenic according to ACMG criteria. CONCLUSION: The present work expands both the geographical distribution of this rare ROC-domain variant and suggests that it may be associated with earlier onset but not necessarily greater disease severity. Continued characterisation of rare LRRK2 variants is essential for refining genotype-phenotype correlations and supporting emerging targeted therapies.

Swiss Medical WeeklyVol. 156(11)
University of Bern (CH), University Hospital of Bern (CH)
Boston Scientific Corporation, Fondation Bertarelli, Institut National de la Santé et de la Recherche Médicale, Louis-Jeantet Foundation, Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung, Association France Parkinson, Fondation Roger de Spoelberch, Merz Pharmaceuticals, Parkinson Vereniging, Idorsia Pharmaceuticals, Parkinson Schweiz, St. Jude Medical
Good health and well-being
Parkinson's Disease Mechanisms and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon